Literature DB >> 31348524

Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach.

Fabio Guolo1,2, Paola Minetto1,2, Marino Clavio1,2, Maurizio Miglino1,2, Nicoletta Colombo1,2, Antonia Cagnetta1,2, Michele Cea1,2, Riccardo Marcolin1,2, Andrea Todiere1,2, Filippo Ballerini1,2, Marco Gobbi1,2, Roberto Massimo Lemoli1,2.   

Abstract

Entities:  

Keywords:  acute leukaemia; minimal residual disease; quantitative PCR

Mesh：

Substances：

Year:  2019        PMID： 31348524     DOI： 10.1111/bjh.16116

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.

Authors:  Ing S Tiong; Richard Dillon; Adam Ivey; Tse-Chieh Teh; Phillip Nguyen; Nicholas Cummings; David C Taussig; Annie-Louise Latif; Nicola E Potter; Manohursingh Runglall; Nigel H Russell; Kavita Raj; Anthony P Schwarer; Chun Yew Fong; Andrew P Grigg; Andrew H Wei
Journal:  Br J Haematol       Date:  2020-05-26       Impact factor: 6.998

2.  Editorial: Acute myeloid leukemia (AML): Is it time for MRD-driven treatment?

Authors:  Fabio Guolo; Claudio Cerchione; Chiara Vernarecci; Alessandro Isidori
Journal:  Front Oncol       Date:  2022-09-09       Impact factor: 5.738
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.